With this agreement, Chong Kun Dang will make a strategic investment in ENCell and conduct research and development for cell and gene therapy using ENCell’s cell and gene therapy development know-how and production technology.
Through this collaboration, the two companies plan to accelerate the joint R&D and production process of advanced biopharmaceuticals, such as chimeric antigen receptor T-cell (CAR-T) treatment and adeno-associated virus (AAV)-based gene therapy.
Chong Kun Dang will conduct global clinical trials by screening target proteins for various solid cancers. Encell will be in charge of process development of gene therapy and production of candidate materials and clinical samples.
An official from Chong Kun Dang said, “Recently, we have secured RNA-based platform technology to increase the possibility of developing it as a cancer vaccine and rare disease treatment, while expanding the scope of new drug development such as gene and cell treatment. We will speed up the development of advanced biopharmaceuticals,” he said.
An ENCELL official said, “We will do our best to produce non-clinical and clinical samples for each pipeline.”
© ‘Global Economic Daily in 5 Languages’ Ajou Economic Daily. Unauthorized reproduction and redistribution prohibited